Payment overview · 2025
General Payments
$1,168.98
63 reported records · 11 companies
Healthcare provider profile · identity verified
Flora Lim
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · GARDENA, CA · NPI 1821699521
Verified facts
What the public records show
CMS Open Payments records show Flora Lim received $1,168.98 in general payments during 2025 across 63 reported records.
Amgen Inc. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Horizant, Jardiance, Linzess, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Prolia by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Horizant by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $392.16 | 33.5% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $222.42 | 19.0% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $179.95 | 15.4% | 8 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $115.90 | 9.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.07 | 7.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.68 | 4.6% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $30.87 | 2.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $26.89 | 2.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.88 | 2.0% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.04 | 1.8% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $19.12 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,168.98 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $251.08 | 16 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $241.61 | 15 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $217.11 | 15 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $179.95 | 8 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $150.82 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $141.08 | 9 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $115.90 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $61.66 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.68 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $30.87 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 123 | exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 148 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
123 | 44 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
169 | 95 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 601 | 180 |
| Losartan Potassium | Losartan Potassium | 397 | 114 |
| Vascepa | Icosapent Ethyl | 347 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 94 |
| Metformin Hcl | Metformin Hcl | 273 | 84 |
| Prolia | Denosumab | 169 | 95 |
| Omeprazole | Omeprazole | 156 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 45 |
| Simvastatin | Simvastatin | 154 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 150 | 47 |
| Jardiance | Empagliflozin | 148 | 27 |
| Lidocaine | Lidocaine | 148 | 33 |
| Alendronate Sodium | Alendronate Sodium | 128 | 43 |
| Icosapent Ethyl | Icosapent Ethyl | 125 | 44 |
| Creon | Lipase/Protease/Amylase | 123 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 59 |
| Gabapentin | Gabapentin | 84 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 29 |
| Fenofibrate | Fenofibrate,micronized | 73 | 24 |
| Meloxicam | Meloxicam | 68 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 20 |
| Trazodone Hcl | Trazodone Hcl | 64 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 60 | 60 |
| Celecoxib | Celecoxib | 58 | 20 |
| Atenolol | Atenolol | 56 | 12 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Trulicity | Dulaglutide | 55 | 12 |
| Lisinopril | Lisinopril | 54 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 53 | 13 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 50 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Linzess | Linaclotide | 43 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 15 |
| Ibuprofen | Ibuprofen | 35 | 20 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | 13 |
| Eliquis | Apixaban | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | 14 |
| Zenpep | Lipase/Protease/Amylase | 32 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | suppressed |
| Finasteride | Finasteride | 31 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 29 |
| Tradjenta | Linagliptin | 29 | suppressed |
| Baclofen | Baclofen | 27 | 12 |
| Restasis | Cyclosporine | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 15 |
| Ztlido | Lidocaine | 25 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Naproxen | Naproxen | 21 | 12 |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Horizant | Gabapentin Enacarbil | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Victoza 2-Pak | Liraglutide | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Digoxin | Digoxin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,168.98 · 63 records | Amgen Inc. | ACCRUFER, CREON, Cologuard Collection Kit, EVENITY, GEMTESA, HORIZANT, JARDIANCE, Kerendia, LINZESS, MOUNJARO, OTEZLA, REPATHA, ZEPBOUND, ZTLido | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error